Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Enterprise Value: 2016-2025

Historic Enterprise Value for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $795.9 million.

  • UroGen Pharma's Enterprise Value rose 179.01% to $795.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $206.4 million, marking a year-over-year increase of 180.37%. This contributed to the annual value of $212.7 million for FY2024, which is 34.75% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Enterprise Value is $795.9 million, which was up 67.67% from $474.7 million recorded in Q2 2025.
  • UroGen Pharma's Enterprise Value's 5-year high stood at $795.9 million during Q3 2025, with a 5-year trough of $61.0 million in Q1 2022.
  • Over the past 3 years, UroGen Pharma's median Enterprise Value value was $313.9 million (recorded in 2025), while the average stood at $340.5 million.
  • Per our database at Business Quant, UroGen Pharma's Enterprise Value crashed by 82.96% in 2022 and then spiked by 210.96% in 2023.
  • UroGen Pharma's Enterprise Value (Quarterly) stood at $124.1 million in 2021, then declined by 15.50% to $104.8 million in 2022, then surged by 210.96% to $326.0 million in 2023, then plummeted by 34.75% to $212.7 million in 2024, then surged by 179.01% to $795.9 million in 2025.
  • Its Enterprise Value was $795.9 million in Q3 2025, compared to $474.7 million in Q2 2025 and $313.9 million in Q1 2025.